Search results
Author(s):
Gurushankar Govindarajan
,
James R Sowers
,
Craig S Stump
Added:
3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is…
View more
Author(s):
Dimitris Tousoulis
,
Evangelos Oikonomou
,
Gerasimos Siasos
,
et al
Added:
3 years ago
Diabetes mellitus (DM) is a group of diseases characterised by metabolic disturbances with increasing prevalence worldwide.1 Individuals with DM present several detrimental micro- and macrovascular complications such as retinopathy, nephropathy, neuropathy, atherosclerosis and coronary heart disease.2,3 Accordingly, efforts for early diagnosis and appropriate management are of ultimate importance…
View more
Author(s):
Marianne Yngen
Added:
3 years ago
Introduction
Diabetes mellitus (DM), characterised by chronic hyperglycaemia, is a rapidly growing worldwide health problem. The prevalence of DM has been estimated at 3% to 5% of Western populations. The incidence of DM is increasing and will more than double within 15 years, mainly due to adverse lifestyle changes with excess caloric intake and reduced physical activity, which in turn will…
View more
Microvascular Complications and Outcome after Drug-eluting Stent Implantation in Diabetic Patients
Author(s):
Carlo Briguori
,
Antonio Colombo
Added:
3 years ago
Article
Author(s):
Roland E Schmieder
Added:
3 years ago
The primary goal in the treatment of hypertensive patients is to achieve the maximum possible reduction in the long-term total risk of cardiovascular (CV) and renal morbidity and mortality. In addition to the lowering of blood pressure (BP) per se, successful realisation of the primary goal of treatment also requires appropriate consideration of co-morbidities.1–3 Although there is some…
View more
Author(s):
Muthiah Vaduganathan
Added:
3 years ago
In this video, Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US) shares the findings from the EMPA-REG OUTCOME trial. The goal of the trial was to assess the cardiovascular (CV) safety of empagliflozin, a sodium–glucose cotransporter 2 (SGLT-2) inhibitor, in patients with type 2 diabetes mellitus (T2DM) at high risk for CV events.
Questions:
1. What is the background of…
View more
Inflammation in Diabetes
Author(s):
Sotirios Tsalamandris
,
Alexios S Antonopoulos
,
Evangelos Oikonomou
,
et al
Added:
3 years ago
Article
Author(s):
Gemma Figtree
Added:
5 years ago
Gemma Figtree discusses the CANVAS trial - canagliflozin and heart failure in type 2 diabetes mellitus.
Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA.
View more
Author(s):
Robert Dalla Pozza
,
Susanne Bechtold
Added:
3 years ago
Atherosclerosis and atherosclerosis-related complications such as coronary, cerebrovascular and peripheral arterial disease show their clinical manifestation in adulthood. However, changes at the endothelial level do not occur suddenly in the elderly, but are the result of a long, on-going, slowly evolving process. We know from autopsy studies that atherosclerotic processes begin in childhood and…
View more
Author(s):
Juan Tamargo
Added:
3 years ago
Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor1–5 and it confers an approximately two- to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD).1,6–8 The prevalence of T2D among patients with HF is as high as 40–45% and that of HF in patients with…
View more